BD Expands U.S. Manufacturing Capacity for Critical Medical Devices to Improve Healthcare Supply Chain
In a bold move to strengthen the healthcare landscape in the United States, BD (Becton, Dickinson and Company), a global frontrunner in medical technology, has declared a substantial investment aimed at expanding its manufacturing capacity for critical medical devices. As part of this initiative, BD will allocate over $10 million in 2024 to enhance its production capabilities for items crucial to healthcare delivery, including syringes, needles, and IV catheters. This strategic decision not only aims to meet the growing demands of the healthcare system but also reflects a commitment to bolstering U.S. manufacturing.
The recent developments include the installation of new production lines for needles and syringes at BD's facilities in Connecticut and Nebraska. One of these lines is operational, with more set to begin production shortly. This expansion is projected to increase BD's output of safety-engineered injection devices by over 40% and conventional syringes by more than 50%, resulting in hundreds of millions of additional units per year. This increase in production is vital for supporting healthcare activities such as vaccinations, medication preparation, and direct drug delivery to patients.
Additionally, BD has made a significant impact on job creation, having hired over 215 new full-time employees at its Nebraska and Connecticut facilities. These teams will contribute to the increased production output, further enhancing BD’s commitment to strengthening the fabric of the U.S. healthcare supply chain.
Furthermore, looking ahead into 2025, BD has earmarked more than $30 million for the expansion of IV line manufacturing at its Utah plant to meet the rising demand for catheter solutions. This follows a previous investment exceeding $2 million in 2024, which already boosted the production capacity for IV catheters by over 40 million units annually.
Eric Borin, president of Medication Delivery Solutions at BD, emphasized the importance of domestic manufacturing, stating, 'By expanding our production capacity, we are not only meeting the critical needs of patients and providers, but we also reinforce our commitment to the nation's healthcare infrastructure.'
This initiative underscores BD's legacy of over 120 years in manufacturing excellence within the U.S. Their facilities in states such as Nebraska, Connecticut, and Utah provide a substantial backbone to the U.S. medical product supply chain, employing over 10,000 people across more than 30 locations.
Notably, facilities in West Virginia, including a significant site in Columbus, Nebraska, established in 1949, are some of the last large-scale syringe manufacturing sites in the country. Today, Columbus spans an impressive 1 million square feet and employs over 2,000 individuals. Similarly, the Canaan, Connecticut site, operational since 1961, spans 385,000 square feet and employs more than 540 staff members. The Sandy, Utah location, inaugurated in 1956, is distinguished as the world's largest producer of IV catheter lines and has approximately 1,200 employees.
BD's commitment doesn’t just center around increasing production capacity; it also reflects a focus on innovative technology. The company has been at the forefront of healthcare advancement by enhancing medical discovery, diagnostic processes, and care delivery. With a team of over 70,000, BD is dedicated to improving safety, efficiency, and access to healthcare worldwide. The company collaborates with global organizations to tackle some of the most pressing health challenges, ultimately enhancing healthcare outcomes and reducing costs for providers and patients alike.
As BD moves forward with these advancements, it sets a prominent example of how investing in domestic manufacturing can significantly benefit public health infrastructure and contribute to a resilient healthcare system in the United States.
The recent developments include the installation of new production lines for needles and syringes at BD's facilities in Connecticut and Nebraska. One of these lines is operational, with more set to begin production shortly. This expansion is projected to increase BD's output of safety-engineered injection devices by over 40% and conventional syringes by more than 50%, resulting in hundreds of millions of additional units per year. This increase in production is vital for supporting healthcare activities such as vaccinations, medication preparation, and direct drug delivery to patients.
Additionally, BD has made a significant impact on job creation, having hired over 215 new full-time employees at its Nebraska and Connecticut facilities. These teams will contribute to the increased production output, further enhancing BD’s commitment to strengthening the fabric of the U.S. healthcare supply chain.
Furthermore, looking ahead into 2025, BD has earmarked more than $30 million for the expansion of IV line manufacturing at its Utah plant to meet the rising demand for catheter solutions. This follows a previous investment exceeding $2 million in 2024, which already boosted the production capacity for IV catheters by over 40 million units annually.
Eric Borin, president of Medication Delivery Solutions at BD, emphasized the importance of domestic manufacturing, stating, 'By expanding our production capacity, we are not only meeting the critical needs of patients and providers, but we also reinforce our commitment to the nation's healthcare infrastructure.'
This initiative underscores BD's legacy of over 120 years in manufacturing excellence within the U.S. Their facilities in states such as Nebraska, Connecticut, and Utah provide a substantial backbone to the U.S. medical product supply chain, employing over 10,000 people across more than 30 locations.
Notably, facilities in West Virginia, including a significant site in Columbus, Nebraska, established in 1949, are some of the last large-scale syringe manufacturing sites in the country. Today, Columbus spans an impressive 1 million square feet and employs over 2,000 individuals. Similarly, the Canaan, Connecticut site, operational since 1961, spans 385,000 square feet and employs more than 540 staff members. The Sandy, Utah location, inaugurated in 1956, is distinguished as the world's largest producer of IV catheter lines and has approximately 1,200 employees.
BD's commitment doesn’t just center around increasing production capacity; it also reflects a focus on innovative technology. The company has been at the forefront of healthcare advancement by enhancing medical discovery, diagnostic processes, and care delivery. With a team of over 70,000, BD is dedicated to improving safety, efficiency, and access to healthcare worldwide. The company collaborates with global organizations to tackle some of the most pressing health challenges, ultimately enhancing healthcare outcomes and reducing costs for providers and patients alike.
As BD moves forward with these advancements, it sets a prominent example of how investing in domestic manufacturing can significantly benefit public health infrastructure and contribute to a resilient healthcare system in the United States.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.